Conversion of estrone to 17 beta-estradiol in Jurkat acute T cell leukemia Hut-78 T- and Raji B lymphoma cell lines in vitro

Biomedicine and Pharmacotherapy

Volumn 67, Issue 4, 2013, Pages 299-303

  Strugała, Aleksander J ^a   Jagodziński, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

17 beta estradiol; HSD17B1; Leukemia; Lymphoma

Indexed keywords

ESTRADIOL; ESTRONE;

ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; T CELL LEUKEMIA;

CELL LINE, TUMOR; ESTRADIOL; ESTRADIOL DEHYDROGENASES; ESTRONE; HUMANS; JURKAT CELLS; LEUKEMIA, T-CELL; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL;

EID: 84876938123     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.11.003     Document Type: Article

References (58)

1. Genazzani A.R., Pluchino N., Luisi S., Luisi M. Estrogen, cognition and female ageing. Hum Reprod Update 2007, 13(2):175-187. Epub 2006 Nov 29.
2. Hojo Y., Murakami G., Mukai H., Higo S., Hatanaka Y., Ogiue-Ikeda M., et al. Estrogen synthesis in the brain-role in synaptic plasticity and memory. Mol Cell Endocrinol 2008, 290:31-43.
3. Giordano C., Montopoli M., Perli E., Orlandi M., Fantin M., Ross-Cisneros F.N., et al. Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. Brain 2011, 134:220-234.
4. Townsend E.A., Sathish V., Thompson M.A., Pabelick C.M., Prakash Y.S. Estrogen effects on human airway smooth muscle involve cAMP and protein kinase A. Am J Physiol Lung Cell Mol Physiol 2012, 303(10):L923-L928.
5. Tsutsui T., Tamura Y., Yagi E., Barrett J.C. Involvement of genotoxic effects in the initiation of estrogen induced cellular transformation: studies using Syrian hamster embryo cells treated with 17 betaestradiol and eight of its metabolites. Int J Cancer 2000, 86:8-14.
6. Kawasaki T., Chaudry I.H. The effects of estrogen on various organs: therapeutic approach for sepsis, trauma, and reperfusion injury. Part 1: central nervous system, lung, and heart. J Anesth 2012, 10.1007/s00540-012-1425-3.
7. McEwen B.S., Alves S.E. Estrogen actions in the central nervous system. Endocr Rev 1999, 20(3):279-307.
8. Lang T.J. Estrogen as an immunomodulator. Clin Immunol 2004, 113(3):224-230.
9. Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 2005, 308(5728):1583-1587.
10. Islander U., Jochems C., Lagerquist M.K., Forsblad-d'Elia H., Carlsten H. Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol 2011, 335(1):14-29.
11. Eliassen A.H., Hankinson S.E. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008, 630:148-165.
12. Cavalieri E.L., Rogan E.G. Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers. Future Oncol 2010, 6:75-91.
13. Bonkhoff H., Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009, 55:533-542.
14. Siegfried J.M., Hershberger P.A., Stabile L.P. Estrogen receptor signaling in lung cancer. Semin Oncol 2009, 36:524-531.
15. Di Leo A., Messa C., Cavallini A., Linsalata M. Estrogens and colorectal cancer. Curr Drug Targets Immune Endocr Metabol Disord 2001, 1:1-12.
16. Ellem S.J., Risbridger G.P. Aromatase and regulating the estrogen: androgen ratio in the prostate gland. J Steroid Biochem Mol Biol 2010, 118:246-251.
17. Yakimchuk K., Norin S., Kimby E., Hägglund H., Warner M., Gustafsson J.å. Up-regulated estrogen receptor b2 in chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53(1):139-144.
18. Yakimchuk K., Iravani M., Hasni M.S., Rhönnstad P., Nilsson S., Jondal M., et al. Effect of ligand-activated estrogen receptor b on lymphoma growth in vitro and in vivo. Leukemia 2011, 25(7):1103-1110.
19. Kane E.V., Roman E., Becker N., Bernstein L., Boffetta P., Bracci P.M., et al. Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies. Ann Oncol 2012, 23(9):2362-2374.
20. Kane E.V., Bernstein L., Bracci P.M., Cerhan J.R., Costas L., Dal Maso L., et al. Postmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies. Ann Oncol 2012, 00:1-9.
21. Gaikwad N.W., Yang L., Weisenburger D.D., Vose J., Beseler C., Rogan E.G., et al. Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma. Biomarkers 2009, 14(7):502-512.
22. Simpson E.R. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003, 86(3-5):225-230.
23. Smuc T., Rizner T.L. Expression of 17-beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines. Chem Biol Interact 2009, 178:228-233.
24. Zhou Z., Shackleton C.H., Pahwa S., White P.C., Speiser P.W. Prominent sex steroid metabolism in human lymphocytes. Mol Cell Endocrinol 1998, 138(1-2):61-69.
25. Xu X., Veenstra T.D. Concentration of endogenous estrogens and estrogen metabolites in the NCI-60 human tumor cell lines. Genome Med 2012, 4(4):31.
26. Aka J.A., Mazumdar M., Lin S.X. Reductive 17-beta-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer. Mol Cell Endocrinol 2009, 301:183-190.
27. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
28. Everaus H. Hormones and immune responsiveness in chronic lymphocytic leukemia. Leuk Lymphoma. 1992, 8(6):483-489.
29. Schnyder S., Du N.T., Le H.B., Singh S., Loredo G.A., Vaughan A.T. Estrogen treatment induces MLL aberrations in human lymphoblastoid cells. Leuk Res 2009, 33(10):1400-1404.
30. Teras L.R., Patel A.V., Hildebrand J.S., Gapstur S.M. Postmenopausal unopposed estrogen and estrogen plus progestin use and risk of non-Hodgkin lymphoma in the American Cancer Society Cancer Prevention Study-II Cohort. Leuk Lymphoma 2012, 10.3109/10428194.2012.722216.
31. Gupta V., Singh S.M. Sex dimorphism in antitumor response of chemotherapeutic drug cisplatin in a murine host-bearing a T-cell lymphoma. Anticancer Drugs 2008, 19(6):583-592.
32. Gupta V., Singh S.M. Gender dimorphism of tumor growth: role of gonadal hormones in differential regulation of apoptosis of a murine T cell lymphoma. J Biomed Sci 2008, 15(2):147-162.
33. Le Romancer M., Poulard C., Cohen P., Sentis S., Renoir J.M., Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr Rev 2011, 32:597-622.
34. Barkhem T., Nilsson S., Gustafsson J.A. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J PharmacoGenomics 2004, 4:19-28.
35. He Y.Y., Du G.Q., Cai B., Yan Q., Zhou L., Chen X.Y., et al. Estrogenic transmembrane receptor of GPR30 mediates invasion and carcinogenesis by endometrial cancer cell line RL95-2. J Cancer Res Clin Oncol 2012, 138(5):775-783.
36. Olde B., Leeb-Lundberg L.M. GPR30/GPER1: searching for a role in estrogen physiology. Trends Endocrinol Metab 2009, 20(8):409-416.
37. Cutolo M., Sulli A., Straub R.H. Estrogen metabolism and autoimmunity. Autoimmun Rev 2012, 11(6-7):A460-A464.
38. Yao J., Huang Q., Zhang X.B., Fu W.L. Promoter CpG methylation of oestrogen receptors in leukaemia. Biosci Rep 2009, 29(4):211-216.
39. Głuszko R., Zielezińska K., Ociepa T., Kamieńska E., Chosia M., Urasiński T., et al. Reed-Sternberg cells in classical Hodgkin lymphoma in children seem to be predominantly oestrogen receptor a negative and oestrogen receptor b positive. Pol J Pathol 2011, 62(2):79-83.
40. Khayr W., Haddad R.Y., Noor S.A. Infections in hematological malignancies. Dis Mon 2012, 58(4):239-249.
41. Rao U., Piccin A., Malone A., O'Hanlon K., Breatnach F., O'Meara A., et al. Utility of bronchoalveolar lavage in the diagnosis of pulmonary infection in children with haematological malignancies. Ir J Med Sci 2012, 10.1007/s11845-012-0852-3.
42. Syrjala K.L., Langer S., Abrams J., Storer B., Martin P. Physical and mental recovery after hematopoietic stem cell transplantation. Discov Med 2004, 4(23):263-269.
43. Cutolo M., Accardo S., Villaggio B., Barone A., Sulli A., Coviello D.A., et al. Androgen and estrogen receptors are present in primary cultures of human synovial macrophages. J Clin Endocrinol Metab 1996, 81(2):820-827.
44. Sakazaki H., Ueno H., Nakamuro K. Estrogen receptor alpha in mouse splenic lymphocytes: possible involvement in immunity. Toxicol Lett 2002, 133(2-3):221-229.
45. Hill L., Jeganathan V., Chinnasamy P., Grimaldi C., Diamond B. Differential roles of estrogen receptors a and b in control of B-cell maturation and selection. Mol Med 2011, 17(3-4):211-220.
46. Wang C., Dehghani B., Magrisso I.J., Rick E.A., Bonhomme E., Cody D.B., et al. GPR30 contributes to estrogen-induced thymic atrophy. Mol Endocrinol 2008, 22(3):636-648. Epub 2007 Dec 6.
47. Pernis A.B. Estrogen and CD4+ T cells. Curr Opin Rheumatol 2007, 19(5):414-420.
48. McMurray R.W., Ndebele K., Hardy K.J., et al. 17-betaestradiol suppresses IL-2 and IL-2 receptor. Cytokine 2001, 14:324-333.
49. Kanda N., Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 1999, 103:282-288.
50. Kanda N., Tsuchida T., Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1999, 42:328-337.
51. Moulton V.R., Holcomb D.R., Zajdel M.C., Tsokos G.C. Estrogen upregulates cyclic AMP response element modulator a expression and downregulates interleukin-2 production by human T lymphocytes. Mol Med 2012, 18(1):370-378.
52. Jun D.Y., Park H.S., Kim J.S., Kim J.S., Park W., Song B.H., et al. 17Alpha estradiol arrests cell cycle progression at G2/M and induces apoptotic cell death inhuman acute leukemia Jurkat T cells. Toxicol Appl Pharmacol 2008, 231(3):401-412. Epub 2008 Jun 4.
53. Miyoshi Y., Ando A., Shiba E., Taguchi T., Tamaki Y., Noguchi S. Involvement of upregulation of 17-beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 2001, 94:685-689.
54. Jansson A. 17-beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J Steroid Biochem Mol Biol 2009, 114:64-67.
55. Blomquist C.H., Bonenfant M., McGinley D.M., Posalaky Z., Lakatua D.J., Tuli-Puri S., et al. Androgenic and estrogenic 17-beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian epithelial tumors: evidence for the type 1, 2 and 5 isoforms. J Steroid Biochem Mol Biol 2002, 81:343-351.
56. Smuc T., Pucelj M.R., Sinkovec J., Husen B., Thole H., Lanisnik Rizner T. Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis. Gynecol Endocrinol 2007, 23:105-111.
57. Saloniemi T., Järvensivu P., Koskimies P., Jokela H., Lamminen T., Ghaem- Maghami S., et al. Novel hydroxysteroid (17-beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice. Am J Pathol 2010, 176:1443-1451.
58. Kasai T., Shozu M., Murakami K., Segawa T., Shinohara K., Nomura K., et al. Increased expression of type I 17-beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma. J Clin Endocrinol Metab 2004, 89:5661-5668.